BioSpace News Archive

Cerus Corporation announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion Congress, taking place in Gothenburg, Sweden, from June 17 through June 21.

Altamira Therapeutics Ltd., a company dedicated to developing therapeutics that address important unmet medical needs, announced that the U.S. Food and Drug Administration has completed its safety review of the Company’s Investigational New Drug application for AM-125 in acute vestibular syndrome.

DepYmed, Inc. is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase family of enzymes.

Vatech, a global leader in the dental imaging market, reported that the digital Intraoral x-ray generator ‘EzRay Air’ series has already been adopted by 50,000 dentists around the world.

IntegriChain and Knipper Health announced a non-exclusive joint initiative to support emerging manufacturers launching new products that need comprehensive 3PL services, order-to-cash, government pricing, and claims adjudication support.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora”) and Sentrx Animal Care (“Sentrx”) announced today they have amended their existing licensing agreement for patents and technology related to Kiora’s KIO-201 product candidate

Pulmatrix, Inc. announced it will present data at the American Headache Society 65th Annual Meeting, being held from June 15th through 18th both virtually and in-person at the J.W. Marriott in Austin, Texas.

Allogene Therapeutics, Inc. at the International Conference on Malignant Lymphoma in Lugano, Switzerland presented updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory large B-cell lymphoma treated with the Alloy™ manufacturing process material across different CAR T dosing and lymphodepletion regimens.

Takeda and HUTCHMED Limited announced that the European Medicines Agency has validated and accepted for regulatory review the marketing authorization application for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer.

Neurona Therapeutics announced the presentation of new data from the open-label, single arm, starting dose-level of its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy.